Effect of Neoadjuvant Systemic Therapy on Surgery of luminal Breast Cancers

Marzieh Mohammadizavieh Breast Surgeon, Arash Women's Hospital, TUMS

Introduction

- The goal of NAC is to improve surgical outcomes
- locally advanced cancers, stage III
- Stage IIB, T3 who desire BCS
- NAC more likely eradicate micrometastatic disease
- HR+,HER2- tumors are less likely to respond to NAC
- Several studies have demonstrated similar outcomes in NAC and adjuvant chemotherapy

NAC in luminalA

- Luminal A encompasses 50-60% all BC
- pCR 8%
- pCR is associated with survival benefit
- pCR prognostic impact is not clear in luminal BC
- 19.2% increase rate of BCS
- 6% convert positive axilla to negative




Figure 2. pCR rates and BCS conversion rates in neoadjuvant chemotherapy by histologic subtype. pCR = pathologic complete response; BCS = breast-conserving surgery; HER2 = human epidermal growth factor receptor 2; TNBC = triple-negative breast cancer.

https://ejbc.kr

https://doi.org/10.4048/jbc.2019.22.e35

416

CR ratio

Biopsy ER and PR status (χ ₂ ² =21-8; p<0-00	01)		
ER+ and PR+	31.9 (83/260)		0.77 (0.64-0.92)
ER+ and PR-	26.6 (21/79)		0.71 (0.50-1.02)
ER- and PR-	35.5 (117/330)	-	1.24 (1.09-1.41)
Unknown	25.4 (325/1278)		0.73 (0.49–1.08)
Table 3			
Pathologic respons	e evaluation.		
pCR, N (%)		9 (7.9)	-
Sataloff grade – primary Tumor, N (%)			—
A		10 (9.3)	
В		50 (46.7)	
С	C		
D		7 (6.5)	
Sataloff grade –	nodal, N (%)		
А	A		
В	В		
С	C		
D		29 (27.4)	
ypN0, N (%)		21 (18.4) 37 (33.6)	
Downstaged, N (Downstaged, N (%)		
Baseline Tumor size, mm, median (IQR)		39 (27–50)	
Post neoadjuvan	t Tumor size, mm, median (IQR)	35 (21-60)	

-2 (-16 - 10)

48 (44.9)

24 (22.4)

35 (32.7)

-6.3(-45.2 - 26.3)

pCR, pathologic complete response.

Change in size, N (%)

Reduced

Increased

Stable

Change in size, mm, median (IQR)

Relative change in size, median % (IQR)

Factors predict response

- Better response in: higher cT, PR-, young, high grade, ductal type, AC-T regimen
- High Ki67 rate is independent prognostic factor in tumor response rate
- Another article:
- cCR: premenopeuse, high grade, high Ki67
- pCR: ductal, high grade, high Ki67
- Low expression of PR only in luminal HER2+ is predictive
- PR+ predicted increased risk of nodal positivity

Table 4. Univariate and multivariate logistic regression analysis of luminal HER2⁻ breast cancer according to the tumor response rate

Variables	OR (95% CI)	p-value	Adjusted OR (95% CI)	<i>p</i> -value
Age (yr)				
< 50	Reference		Reference	
≥ 50	1.931 (0.909-4.105)	0.087	1.368 (0.573-3.265)	0.481
Clinical tumor stage				
Low (T1, T2)	Reference		Reference	
High (T3, T4)	0.517 (0.237-1.128)	0.098	0.693 (0.279-1.721)	0.430
Clinical nodal stage				
Low (N1)	Reference		Reference	
High (N2, N3)	2.290 (0.987-5.310)	0.054	2.315 (0.923-5.805)	0.073
PR				
Negative	Reference		Reference	
Positive	0.797 (0.335-1.895)	0.608	0.906 (0.330-2.486)	0.847
Ki-67 expression				
Low (< 14%)	Reference		Reference	
High (≥ 14%)	3.341 (1.541-7.241)	0.002	2.478 (1.066-5.762)	0.035
Histologic grade				
Low (grade 1 or 2)	Reference		Reference	
High (grade 3)	2.442 (0.673-8.865)	0.175	1.256 (0.271-5.820)	0.771
BCS conversion				
No	Reference		Reference	
Yes	5.083 (1.317-19.617)	0.018	5.793 (1.358-24.708)	0.018
Axilla pCR				
No	Reference		Reference	
Yes	3.937 (1.539-10.073)	0.004	3.715 (1.356-10.177)	0.011

HER2 = human epidermal growth factor receptor 2; OR = odd ratio; CI = confidence interval; PR = progesterone receptor; BCS = breast conserving surgery; pCR = pathologic complete response.

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)*

- Meta-analysis from 10 randomised trials
- 1983-2002
- med FU 9y, last FU 2013
- pCR is higher in ER- patients
- higher local recurrence after NAC
- no difference in mortality




Figure 2: Effect of neoadjuvant versus adjuvant chemotherapy on recurrence and mortality

Local recurrence (A), distant recurrence (B), breast cancer mortality (C), and death from any cause (D). Three trials recorded causes of any deaths but only the first breast cancer event. Hence, for these trials, distant recurrence includes the first distant recurrence as the first event and death from breast cancer. Error bars are 95% CIs. NACT=neoadjuvant chemotherapy. O-E=observed minus expected. RR=rate ratio. V=variance of O-E.


1

. .

NAC vs NET

- Similar BCS rate
- More pCR in NAC
- Greater survival rate
 in NAC
 Figure. Kaplan-Meier Survival

Figure. Kaplan-Meier Survival Curve for Overall Survival in Patients With Strongly Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Invasive Ductal Carcinoma Receiving Neoadjuvant Treatments



JAMA Network Open. 2021;4(3):e211785. doi:10.1001/jamanetworkopen.2021.1785


- low pCR is not a sufficient reason to hesitate performing NAC in luminal BC
- NAC provides reduction in tumor size and consequently improve BCS rate
- NICE guidelines recommendation: T>5cm with >4 involved node or borderline breast, axilla conservable

National Comprehensive Cancer Network®

NCCN Guidelines Version 8.2021 Invasive Breast Cancer

NCCN Guidelines Index Table of Contents Discussion

SURGICAL AXILLARY STAGING



Thanks for your attention

